Search Results - "Burstein, H.J."

Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer.

Authors: Burstein, H.J. Curigliano, G. Gnant, M. et al.

Source: Annals of Oncology. Dec2025, Vol. 36 Issue 12, p1433-1446. 14p.

Long-term outcomes with adjuvant CDK4/6 inhibitors: who benefits most?

Authors: O'Meara, T.A. Burstein, H.J.

Source: Annals of Oncology. Feb2026, Vol. 37 Issue 2, p133-135. 3p.

Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023.

Authors: Curigliano, G. Burstein, H.J. Gnant, M. et al.

Source: Annals of Oncology. Nov2023, Vol. 34 Issue 11, p970-986. 17p.

Experts' perspectives on the role of medical marijuana in oncology: A semistructured interview study.

Authors: Braun, I.M. Meyer, F.L. Gagne, J.J. et al.

Source: Psycho-Oncology. Aug2017, Vol. 26 Issue 8, p1087-1092. 6p. 2 Charts.

Subjects: Oncology, Medical marijuana, Medicinal plants, Expert evidence, Opioids, Benzodiazepines

Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?

Authors: Tarantino, P. Burstein, H.J. Lin, N.U. et al.

Source: Annals of Oncology. Mar2022, Vol. 33 Issue 3, p234-238. 5p.

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

Authors: Burstein, H.J. Curigliano, G. Thürlimann, B. et al.

Source: Annals of Oncology. Oct2021, Vol. 32 Issue 10, p1216-1235. 20p.

Corrigendum to "Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023": [Annals of Oncology 34 (2023) 970-986].

Authors: Curigliano, G. Burstein, H.J. Gnant, M. et al.

Source: Annals of Oncology. Mar2025, Vol. 36 Issue 3, p351-351. 1p.

Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification.

Authors: Trapani, D. Franzoi, M.A. Burstein, H.J. et al.

Source: Annals of Oncology. Jul2022, Vol. 33 Issue 7, p702-712. 11p.

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Authors: Loibl, S. André, F. Bachelot, T. et al.

Source: Annals of Oncology. Feb2024, Vol. 35 Issue 2, p159-182. 24p.

ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.

Authors: Tarantino, P. Viale, G. Press, M.F. et al.

Source: Annals of Oncology. Aug2023, Vol. 34 Issue 8, p645-659. 15p.

Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer.

Authors: Bellon, J.R. Tayob, N. Burstein, H.J. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. 2021 Supplement, Vol. 111 Issue 3, pS34-S34. 1p.

Subjects: HER2 positive breast cancer, Hormone receptors, Breast cancer

The legacy of Professor Aron Goldhirsch.

Authors: Gelber, R.D. Coates, A.S. Gelber, S. et al.

Source: Annals of Oncology. Jun2020, Vol. 31 Issue 6, p671-673. 3p. 1 Color Photograph.

Concurrent Trastuzumab and Radiation Therapy (RT) in the Adjuvant Treatment of Breast Cancer

Authors: Bellon, J.R. Gover, M.T. Burstein, H.J. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. Oct2005 Supplement 1, Vol. 63, pS55-S56. 0p.

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809

Authors: Shapiro, C.L. Halabi, S. Hars, V. et al.

Source: European Journal of Cancer. Mar2011, Vol. 47 Issue 5, p683-689. 7p.

Use of alternative medicine by women with early-stage breast cancer.

Authors: Burstein, H.J. Gelber, S. Guadagnoli, E. et al.

Source: Alternative therapies in health and medicine Sep99; Vol. 5 (5).

Journal Info: Publisher: InnoVisions Professional Media ISSN: 1078-6791